Pharmacological Treatment of Substance Abuse Disorders

Psychiatry: Third Edition

Volumn 2, Issue , 2008, Pages 2390-2416

  Raby, Wilfrid Noel ^a   Levin, Frances R ^a,b   Nunes, Edward V ^a   Roose, Steven P ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Alcohol; Marijuana; Nicotine; Opiate; Pharmacology; Stimulants; Substance abuse; Treatment

Indexed keywords

EID: 76749125195     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470515167.ch111     Document Type: Chapter

References (200)

1. Addolorato G, Leggio L, Abenavoli L, et al. (2006) Baclofen in the treatment o falcohol withdrawal syndrome: a comparative study vs. diazepam. American Journal of Medicine 119, 276. e13-276. e18.
2. Amass L, Ling W, Freese TE, et al. (2004) Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. American Journal on Addictions 13 (Suppl. 1), S42-S66.
3. Anggadiredja K, Nakamichi M, Hiranita T, et al. (2004) Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade.. Neuropsychopharmacology 29, 1470-1478.
4. Anton RF, O'Malley SS, Ciraulo DA, et al. (2006) Combined pharmacotherapy and behavioral interventions for alcohol dependence. JAMA 295, 2003-2017.
5. Arseneault L, Cannon M, Witton J, et al. (2004) Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 84, 110-117.
6. Ascher JA, Cole JO, Colin JN, et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry 56, 395-401.
7. Auriacombe M, Fatseas M, Dubernet J, et al. (2004) French field experience with buprenorphine. American Journal on Addictions 13 (Suppl. 1), S17-S28.
8. Ball JC, Lange WR, and Myers E (1988) Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior 29, 214-226.
9. Ballenger JC and Post RM (1978) Kindling as a model for alcohol withdrawal syndromes. British Journal of Psychiatry 133, 1-14.
10. Bart G, Kreek MJ, Ott J, et al. (2005) Increased attributable risk related to a functional mu-opiod receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30, 417-422.
11. Barthwell A, Senay E, and Marks R (1989) Patients successfully maintained with methadone escaped human immunodeficiency virus infection. Archives of General Psychiatry 46, 957.
12. Bearn J, Gossop M, and Strang J (1996) Randomized double-blind comparison of lofexidine and methadone in the in-patient treatment of opioid withdrawal. Drug and Alcohol Dependence 43, 87-91.
13. Becker HC, Myrick H, and Veatch LM (2006) Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol and Alcoholism 41, 399-406.
14. Berglund M, Thelander S, Salaspuro M, et al. (2003) Treatment of alcohol abuse. Alcoholism, Clinical and Experimental Research 27, 1645-1656.
15. Berlin RG (1989) Disulfiram toxicity: a consideration of biochemical mechanism and clinical spectrum. Alcohol and Alcoholism 24, 241-246.
16. Berrettini WH, Wileyto EP, Epstein L, et al. (2007) Catechol-O-Methyl-transferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biological Psychiatry 61, 111-118.
17. Besson M, David V, Suarez S, et al. (2006) Genetic dissociation of two behaviors associated with nicotine addiction: Beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal. Psychopharmacology (Berlin) 187, 189-199.
18. Bisaga A, Aharonovich E, Garawi F, et al. (2006) A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug and Alcohol Dependence 81, 267-274.
19. Bohadana A, Nilsson F, Rasmussen T, et al. (2000) Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: A randomized, double-blind, placebo-controlled trial. Archives of Internal Medicine 160, 3128-3134.
20. Boothby LA and Doering PL (2005) Acamprosate for the treatment of alcohol dependence. Clinical Therapeutics 27, 695-714.
21. Boothby LA and Doering PL (2007) Buprenorphine for the treatment of opioid dependence. American Journal of Health-System Pharmacy 64, 266-272.
22. Brady KT, Sonne S, Anton RF, et al. (2005) Sertraline in the treatment of co-occuring alcohol dependence and posttraumatic stress disorder. Alcohol, Clinical and Experimental Research 29, 395-401.
23. Brongers GA (1964) Nicotiana Tobacum. The History of Tobacco and Tobacco Smoking in the Netherlands. Groningen, Netherlands p 32.
24. Brooks AC, Arnheim P, Carpenter KM, et al. (2006) Patient commitment language strength predicts outcome in behavioral naltrexone therapy involving significant others. Abstract 105. College on Problems of Drug Dependence (June 19), Scottsdale, AZ, USA.
25. Budney AJ, Moore BA, Vandrey RG, et al. (2003) The time course and significance of cannabis withdrawal. Journal of Abnormal Psychology 112, 393-402.
26. Carroll KM, Ball SA, Nich D, et al. (2001) Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: Efficacy of contingency management and significant other involvement. Archives of General Psychiatry 58, 755-761.
27. Carroll KM, Fenton LR, Ball SA, et al. (2004) Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients. Archives of General Psychiatry 61, 264-272.
28. Carroll KM, Rounsaville BJ, Gordon LT, et al. (1994) Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Archives of General Psychiatry 51, 177-187.
29. Carroll KM, Ziedonis D, and O'Malley S (1993) Pharmacological interventions for alcohol-and cocaine-abusing individuals. American Journal on Addictions 2, 77-79.
30. Center for Substance Abuse Treatment (2004) Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction, TIP Series no. 40. Rockville, MD, USA.
31. Cheskin LJ, Fudala PJ, and Johnson RE (1994) A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence 36, 115-121.
32. Cicero TJ, Inciardi JA, and Munoz A (2005) Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004. Journal of Pain and Symptom Management 6, 662-672.
33. Collins ED, Kleber HD, Whittington RA, et al. (2005) Anesthesia-assisted vs buprenorphine-or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 294, 903-913.
34. Comer SD and Collins ED (2002) Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. Journal of Pharmacology and Experimental Therapeutics 303, 695-703.
35. Cone EJ, Welsh P, and Lange WR (1988) Clonidine partially blocks the physiological effects, but not the subjective effects produced by smoking marijuana in male human subjects. Pharmacology, Biochemistry and Behavior 29, 649-652.
36. Covey LS, Glassman AH, and Stetner F (1997) Major depression following smoking cessation. American Journal of Psychiatry 154, 263-265.
37. Croghan IT, Hurt RD, Dakhil SR, et al. (2007) Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clinic Proceedings 82, 186-195.
38. Dackis CA, Kampman KM, Lynch KG, et al. (2005) A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30(1), 205-211.
39. Daeppen JB, Gache P, Landry U, et al. (2002) Symptom-triggered vs. fixed-schedule doses of benzodiazepine for alcohol withdrawal. Archives Internationales de Pharmacodynamie et de Therapie 162, 1117-1121.
40. Dale LC, Ebbert JO, Glover ED, et al. (2007) Bupropion SR for the treatment of smokeless tobacco use. Drug and Alcohol Dependence 90(1), 56-63.
41. Devenyi P and Saunders S (1986) Physicians' Handbook for Medical Management of Alcohol and Drug-Related Problems. Addiction Research Foundation, Toronto, Ontario, Canada.
42. Dole VP and Nyswander M (1965) A medical treatment for diacetylmor-phine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 193, 646-650.
43. Dunbar JL, Turncliff RZ, and Donq Q (2006) Single-and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcoholism, Clinical and Experimental Research 30, 480-490.
44. Ebbert JO, Dale LC, Severson H, et al. (2007) Nicotine lozenges for the treatment of smokeless tobacco use. Nicotine and Tobacco Research 9, 233-240.
45. Ebner N, Rohrmeister K, Winklbaur B, et al. (2007) Management of neonatal abstinence syndrome in neonate born to opioid maintained women. Drug and Alcohol Dependence 87(2/3), 131-138.
46. Ewing JA (1984) Detecting alcoholism. The CAGE questionnaire. JAMA 252(14), 1905-1907.
47. Fals-Stewart W and O'Farrell TJ (2003) Behavioral family counseling and naltrexone for male opioid-dependent. Journal of Consulting and Clinical Psychology 71, 432-442.
48. Favrat B, Zimmermann G, Zullino D, et al. (2006) Opioids antagonist detoxification under anesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: A randomized clinical trial. Drug and Alcohol Dependence 81, 109-116.
49. FDA (2006) www.fda.gov/cder/drug/advisory/methadone.htm.
50. Finnegan LP and Kaltenbach K (1992) Neonatal abstinence syndrome. In Primary Pediatric Care, 3rd edition, Hoekelman RA, Friedman SB, and Nelson NM (eds). CV Mosby, St-Louis, MO, USA, pp 1367-1378.
51. Fowler JS, Logan J, Wang GJ, et al. (2003) Monoamine oxidase and cigarette smoking. Neuro toxicology and Teratology 24, 75-82.
52. Freud S (1884) Ueber Coca. Centralblatt für die gesammte Therapie 2. 289-314.
53. Fudala PJ, Bridge TP, Herbert S, et al. (2003) Office-Based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 349, 949-958.
54. Fuller RD and Williford WO (1980) Life-table analysis of abstinence in a study evaluating the efficacy of disulfiram. Alcoholism, Clinical and Experimental Research 4, 298-301.
55. Galanter M (1993) Network Therapy for Addictions. A New Approach. Basic Books, New York, USA.
56. Garbutt JC, Kranzler HR, and O'Malley SS (2005) Efficacy and tolerabil-ity of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA 293, 1617-1625.
57. Garbutt JC, West SL, and Carey TS (1999) Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA 282, 1318-1325.
58. Gawin FH, Kleber HD, Byck R, et al. (1989) Desipramine facilitation of initial cocaine abstinence. Archives of General Psychiatry 117-121.
59. George TP and O'Malley SS (2004) Current pharmacological treatments for nicotine dependence. Trends in Pharmacological Sciences 25, 42-48.
60. Gerrein JR, Rosenberg C, and Manohar V (1973) Disulfiram maintenance in outpatient treatment of alcoholism. Archives of General Psychiatry 28, 798-802.
61. Gianoulakis C, Krishnan B, and Thavundavil J (1996) Enhanced sensitivity of pituitary beta-endorphin to ethanol in subject at high risk of alcoholism. Archives of General Psychiatry 53, 250-257.
62. Ginawi OT, Al-Majed A A, and Al-Suwailem AK (2005) NAN-190, a possible specific antagonist for methamphetamine. Regulatory Toxicology and Pharmacology 41, 122-127.
63. Giovino GA (2002) Epidemiology of tobacco use in the United States. Oncogene Research 21, 7326-7340.
64. Gonzales D, Rennard SI, Nides M, et al. (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296, 47-55.
65. Gonzalez G, Desai R, Sofuoglu M, et al. (2007) Clinical efficacy of gabap-entin vs. tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug and Alcohol Dependence 87, 1-9.
66. Gonzalez G, Feingold A, Oliveto A, et al. (2003) Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. American Journal of Drug and Alcohol Abuse 29, 497-514.
67. Gotti C, Zoli M, and Clementi F (2006) Brain nicotinic acetylcholine receptors: Native subtypes and their relevance. Trends in Pharmacological Sciences 27, 482-491.
68. Grabowski J, Rhoades H, Stotts A, et al. (2004) Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials. Neuropsycho pharmacology 29(5), 969-981.
69. Hall SM, Humfleet GL, Reus VI, et al. (2004) Extended nortriptyline and psychological treatment for cigarette smoking. American Journal of Psychiatry 161, 2100-2107.
70. Handlesman L, Cochrane KJ, Aronson MJ, et al. (1987) Two new rating scales for opiate withdrawal. American Journal of Drug and Alcohol Abuse 13, 293-308.
71. Haney M, Hart CL, and Foltin RW (2006) Effects of baclofen on cocaine self-administration: opioid and nonopioid-dependent volunteers. Neuropsychopharmacology 31, 1814-1821.
72. Haney M, Hart CL, Vosburg SK, et al. (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29, 158-170.
73. Hardman JG, Limbird LE, and Goodman Gilman A (2001) The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, USA, p. 606.
74. Hasin D, Samet S, Nunes E, et al. (2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. American Journal of Psychiatry 163, 689-696.
75. Hawley RJ, Major LF, Schulman EA, et al. (1985) Cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol and norepinephrine levels in alcohol withdrawal. Correlation with clinical signs. Archives of General Psychiatry 42, 1056-1062.
76. Herman BH and O'Brien CP (1997) Clinical medications development for opiate addiction: focus on nonopioids and opioids antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Seminars in Neuroscience 9, 158-172.
77. Hernandez-Avila CA, Song C, Kuo L, et al. (2006) Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcoholism, Clinical and Experimental Research 30, 860-865.
78. Huestis MA, Boyd SJ, Heishman SJ, et al. (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology [epub ahead of print]. DOI: xxxx
79. Hughes JR, Stead LF, and Lancaster T (2005) Nortriptyline for smoking cessation: A review. Nicotine and Tobacco Research 7, 491-499.
80. Hurt RD, Sachs DP, Glover ED, et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine 337, 1195-1202.
81. Jainsky DR, Johnson RE, Kocher TR, et al. (1985) Clonidine in morphine withdrawal: Differential effects on signs and symptoms. Archives of General Psychiatry 42, 1063-1066.
82. Johansson BA, Berglund M, and Lindgren A (2006) Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 101, 491-503.
83. Johnson BA, Cloninger CR, Roache JD, et al. (2000a) Age of onset as a discriminator between alcoholic subtypes in a treatment-seeking outpatient population.American Journal on Addictions9, 17-27.
84. Johnson RE, Chutuape MA, Strain EC, et al. (2000b) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.The New England Journal of Medicine343, 1290-1297.
85. Johnson BA, Ait-Daoud N, Bowder CL, et al. (2003) Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 361, 1677-1685.
86. Jorenby DE, Hays JT, Rigotti NA, et al. (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296, 56-63.
87. Jorenby DE, Leischow SJ, Nides MA, et al. (1999) A controlled trial of sus-tained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine 340, 685-691.
88. Joy JE, Watson SJ, and Benson JA (eds) (1999) Marijuana and Medicine: Assessing the Science Base. National Academy Press. Washington, DC, USA.
89. Jung YC and Namkoong K (2006) Pharmacotherapy for alcohol dependence: Anticraving medications for relapse prevention. Yonsei Medical Journal 47, 167-178.
90. Kakko J, Svanborg KD, and Kreek MJ (2003) 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 361, 662-668.
91. Kampman KM, Pettinati H, Lynch KG, et al. (2004) A pilot trial of topira-mate for the treatment of cocaine dependence. Drug and Alcohol Dependence 75, 233-240.
92. Kiefer F, Jahn H, and Tarnaske T (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Archives of General Psychiatry 60, 92-99.
93. Kleber HD (1981) Detoxification from narcotics. In Substance Abuse: Clinical Issues and Perspectives. Lowinson JH and Ruiz P (eds). Williams and Wilkins, Baltimore, USA, pp 317-339.
94. Kleber HD (1999) Opioids: Detoxification. In Textbook of Substance Abuse Treatment, 2nd edition, Galanter M and Kleber HD (eds). The American Psychiatric Press, Washington, DC, USA, pp 251-269.
95. Kosten T, Falcioni J, Oliveto A, et al. (2004) Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. American Journal on Addictions 13, 191-201.
96. Kranzler HR, Burleson JA, Brown J, et al. (1996) Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcoholism, Clinical and Experimental Research 20, 1534-1541.
97. Kranzler HR, Burleson JA, Del Boca FK, et al. (1994) Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Archives of General Psychiatry 51, 720-731.
98. Kranzler HR and Van Kirk J (2001) Efficacy of naltrexone and acampro-sate for alcoholism treatment: a meta-analysis. Alcoholism, Clinical and Experimental Research 25, 1335-1341.
99. Kranzler HR, Wesson DR, and Billot L (2004) Naltrexone depot for treatment of alcohol dependence: a multi-center, randomized, placebo-controlled trial. Alcoholism, Clinical and Experimental Research 28, 1051-1059.
100. Kreek MJ (1979) Methadone in treatment: physiological and pharmacological issues. In Handbook on Drug Abuse, Dupont RL, Goldstein A, and O'Donnell J (eds). National Institute on Drug Abuse. Rockville, MD, USA, pp 57-86.
101. Kubota T, Nakajima-Taniguchi C, Fukuda T, et al. (2006) CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics Journal 6, 115-119.
102. Lamberty Y, Gower AJ, and Klitgaard H (2002) The new antiepileptic drug levetiracetam normalizes chlordiazepoxide withdrawal-induced anxiety in mice. European Journal of Pharmacology 439, 101-106.
103. Lee JH, Jang MK, Lee JY, et al. (2005) Clinical predictors for delirium tremens in alcohol dependence. European Journal of Gastroenterology and Hepatology 20, 1833-1837.
104. Levin FR, Evans SM, Brooks DJ, et al. (2006) Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion, and placebo. Drug and Alcohol Dependence 81, 137-148.
105. Levin FR, Evans SM, Brooks DJ, et al. (2007) Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence 87, 20-29.
106. Lhuillier L, Mombereau C, Cryan JF, et al. (2007) GABA(B) receptor positive modulation decreases selective molecular and behavioral effects of cocaine. Neuropsychopharmacology 32, 388-398.
107. Li T-K, Hewitt BG, and Grant BF (2007) Is there a future for quantifying drinking in the diagnosis, treatment, and prevention of alcohol use disorders? Alcohol and Alcoholism. 42(2), 57-63.
108. Liao KF, Peng CY, Lai SW, et al. (2006) Descriptive epidemiology of hepatitis C virus among male heroin users in Taiwan. Southern Medical Journal 99, 348-351.
109. Ling W, Amass L, Shoptaw S, et al. (2005) A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100, 1090-1100.
110. Malaiyandi V, Sellers EM, and Tyndale RF (2005) Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Perspectives in Clinical Pharmacology 77, 145-158.
111. Malcolm R, Ballenger JC, Sturgis ET, et al. (1989) Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. American Journal of Psychiatry 146, 617-621.
112. Mann K, Lehert P, and Morgan NY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcoholism, Clinical and Experimental Research 28, 51-63.
113. Mariani JJ and Levin FR (2004) Pharmacotherapy for alcohol-related disorders: what clinicians should know. Harvard Review of Psychiatry 12(Nov/Dec), 351-366.
114. Mariani JJ, Rosenthal RN, Tross S, et al. (2006) A randomized, open-label, controlled trial of gabapentin and Phenobarbital in the treatment of alcohol withdrawal. American Journal on Addictions 15, 76-84.
115. Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18, 135-174.
116. Marsch LA, Bickel WK, Badger GJ, et al. (2005) Buprenorphine treatment for opiate dependence: the relative efficacy of daily, twice, and thrice weekly dosing. Drug and Alcohol Dependence 77, 195-204.
117. Mason BJ (2003) Acamprosate and naltrexone treatment for alcohol dependence. European Neuropsychopharmacology 13, 469-475.
118. Mattick RP, Kimber J, Breen C, et al. (2004) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence [computer file]. The Cochrane Database of Systematic Reviews 3, CD002207.
119. Mayo-Smith MF (for the American Society of Addiction Medicine) (1997) Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guidelines. JAMA 278, 144-151.
120. McCance-Katz EF (2004) Office-based buprenorphine treatment for opioid-dependent patients. Harvard Review of Psychiatry 12, 321-338.
121. McCance-Katz EF, Price LH, and Kosten TR (1993) Concurrent cocaine and ethanol ingestion in humans: pharmacology, physiology, and role of cocaethylene. Psychopharmacology 111, 39-46.
122. McDowell D, Nunes EV, Seracini AM, et al. (2005) Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial. Drug and Alcohol Dependence 80, 209-221.
123. McLellan AT, Arndt IO, Metzger DS, et al. (1993) The effects of psychosocial services in substance abuse treatment. JAMA 269, 1953-1959.
124. McNicholas L (2004) Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioids Addiction: A Treatment Improvement Protocol (TIP 40). Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, Rockville, MD, USA.
125. Messina ES, Tyndale RF, and Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 282, 1608-1614.
126. Missenden M and Reese AS (2006) Clinical correlates of accelerated aging: multiple stem cell lineage depression in addiction. College on Problems in Drug Dependence, Annual Meeting, Scottsdale, AZ, USA, poster 140.
127. Morley KC, Teesson M, Reid SC, et al. (2006) Naltrexone versus acampro-sate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101, 1451-1462.
128. Mueller TL, Stout RL, and Rudden S (1997) A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcoholism, Clinical and Experimental Research 21, 86-92.
129. Myrick H, Taylor B, LaRowe S, et al. (2005) A retrospective chart review comparing tiagabine and benzodiazepine for the treatment of alcohol withdrawal. Journal of Psychoactive Drugs 37, 409-414.
130. NIH State-of-the-Science Conference Statement on Tobacco Use (2006): Prevention Cessation, and Control. NIH Consensus. State Science Statements 23, 1-26.
131. Novick DM, Joseph H, Croxson TS, et al. (1990) Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Archives of Internal Medicine 150, 97-99.
132. Ntais C, Pakos E, Kyzas P, et al. (2005) Benzodiazepines for alcohol withdrawal [computer file]. The Cochrane Database of Systematic Reviews 3, CD05063.
133. Nunes EV and Levin FR (2004) Treatment of depression in patients with alcohol dependence or other drug dependence: a meta-analysis. JAMA 291, 1887-1896.
134. Nunes EV, McGrath PJ, Quitkin FM, et al. (1995) Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug and Alcohol Dependence 39, 185-195.
135. Nunes EV, Quitkin FM, Donovan SJ, et al. (1998) Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Archives of General Psychiatry 55, 153-160.
136. Nunes EV and Raby WN (2005) Comorbidity of Depression and Substance Abuse. In Biology of Depression: From Novel Insights to Therapeutic Strategies, Licinio J and Wong ML (eds). Wiley, New York, USA, pp 341-364.
137. Nunes EV, Rothenberg JL, Sullivan MA, et al. (2006) Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? American Journal of Drug and Alcohol Abuse 32, 503-517.
138. Nuss MA, Elmicki DM, Dunsworth TS, et al. (2004) Utilizing CIWA-Ar to assess use of benzodiazepine in patients vulnerable to alcohol withdrawal syndrome. West Virginia Medical Journal 100, 21-25.
139. O'Brien CP and Cornish JW (1999) Opioids: antagonists and partial agonists. In Textbook of Substance Abuse Treatment, Galenter M and Kle-ber HD (eds). The American Psychiatric Press, Washington, DC, USA, pp 281-294.
140. O'Connor PG, Carroll KM, Shi JM, et al. (1997) Three methods of opioid detoxification in a primary care setting: a randomized trial. Annals of Internal Medicine 127, 526-530.
141. O'Connor PG and Kosten TR (1998) Rapid and ultra-rapid opioid detoxification techniques. JAMA 279, 229-234.
142. Olincy A, Harris JG, Johnson LL, et al. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Archives of General Psychiatry 63, 630-638.
143. O'Malley SS, Jaffe AJ, Chang G, et al. (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Archives of General Psychiatry 49, 881-887.
144. Orwig D, Brandt N, and Gruber-Baldini AL (2006) Medication management assessment for older adults in the community. Gerontologist 46, 661-668.
145. Oslin DW, Berrettini WH, O'Brien CP, et al. (2006) Targetting treatments for alcohol dependence: The pharmacogenetics of haltrexone. Addiction Biology 11, 397-403.
146. Pelic P and Myrick H (2003) Who is at greatest risk for delirium tremens? Current Psychiatry 2, 14-18.
147. Petry NM, Bickel WK, Piasecki D, et al. (2000) Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. American Journal on Addictions 9, 265-269.
148. Pettinati HM, O'Brien CP, Rabinowitz AR, et al. (2006) The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. Journal of Clinical Psychopharmacology 26, 610-625.
149. Pettinati HM, Volpicelli JR, Kranzler HR, et al. (2000) Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcoholism, Clinical and Experimental Research 24, 1041-1049.
150. Physician's Desk Reference (2006) Physician's Desk Reference, Thomson PDR, Montvale, NJ, USA.
151. Pierce JM, Petry NM, Stitzer ML, et al. (2006) Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Archives of General Psychiatry 63, 201-208.
152. Poling J, Oliveto A, Petry N, et al. (2006) Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Archives of General Psychiatry 63, 219-228.
153. Polycarpou A, Papanikolaou P, Ioannidis JP, et al. (2005) Anticonvulsants for alcohol withdrawal. The Cochrane Database of Systematic Reviews 3, CD005064.
154. Preston KL, Silverman K, Umbricht A, et al. (1999) Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence 54, 125-137.
155. Ranaldi R and Poeggels K (2002) Baclofen decreases methamphetamine self-administration in rats. Neuroreport 13, 1107-1110.
156. Ray LA and Hutchison KE (2004) A polymorphism of the mu-opiod receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol, Clinical and Experimental Research 28, 1789-1795.
157. Reis RK, Roy-Byrne PP, and Ward NG (1989) Carbamazepine treatment for alcohol withdrawal. American Journal of Psychiatry 146, 536-537.
158. Renzelli CM and Capretto NA (2006) Less pain, more gain: buprenor-phine-naloxone and patient retention in treatment. Journal of Addictive Diseases 25, 97-104.
159. Ritter AJ (2002) Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Australian and New Zealand Journal of Psychiatry 36, 224-228.
160. Romach MK and Sellers EM (1991) Management of the alcohol withdrawal syndrome. Annual Review of Medicine 42, 323-340.
161. Rosen MI, Dieckhaus K, McMahon TJ, et al. (2007) Aids Patient Care and STDS 21, 30-40.
162. Saha TD, Stinson FS, and Grant BF (2007) The role of alcohol consumption in future classifications of alcohol use disorders. Drug and Alcohol Dependence, 89(1), 82-92.
163. Saitz R, Mayo-Smith MF, Roberts MS, et al. (1994) Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA 272, 519-523.
164. Schmitz JM, Averill P, Stotts AL, et al. (2001) Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug and Alcohol Dependence 63, 207-214.
165. Schweizer E, Rickels K, and Case WG (1991) Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Archives of General Psychiatry 48, 448-452.
166. Sell SL, McMahon LR, Koek W, et al. (2005) Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys. Behavioural Pharmacology 16, 53-58.
167. Sellers EM and Kalant H (1982) Alcohol withdrawal and delirium tremens. In Encyclopedic Handbook of Alcoholism, Pettison EM and Kaufman E (eds). Gardner, New York, USA, pp 147-166.
168. Sellers EM and Tyndale RF (2000) Mimicking gene defects to treat drug dependence. Annals of the New York Academy of Sciences 909, 233-246.
169. Senay EC (1999) Opioids: Methadone maintenance. In Textbook of Substance Abuse Treatment, 2nd edition, Galanter M and Kleber HD (eds). The American Psychiatric Press, Washington, DC, USA, pp 271-279.
170. Sereny G, Sharma V, and Holt J (1986) Mandatory supervised Antabuse therapy in an outpatient alcoholism program: a pilot study. Alcoholism, Clinical and Experimental Research 10, 290-292.
171. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. (2003) Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. Journal of Clinical Psychiatry 64, 1440-1448.
172. Silagy C, Lancaster T, Stead L, et al. (2004) Nicotine replacement therapy for smoking cessation [computer file]. The Cochrane Database of Systematic Reviews 3, CD000146.
173. Slemmer JE, Martin BR, and Damaj MI (2000) Bupropion is a nicotinic antagonist. Journal of Pharmacology and Experimental Therapeutics 295, 321-327.
174. Soyka M, Apelt SM, Lieb M, et al. (2006) One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study of 2694 patients. Journal of Clinical Psychopharmacology 26, 657-660.
175. Srisurapanont M and Jarusuraisin N (2002) Opioid antagonists for alcohol dependence [computer file]. The Cochrane Database of Systematic Reviews CD001867.
176. Steinberg MB, Foulds J, Richardson DL, et al. (2006) Pharmacotherapy and smoking cessation at tobacco dependence clinic. Preventive Medicine 42, 114-119.
177. Stoller K, Walsh SL, Bigelow GE, et al. (2001) Effects of buprenorphine/ naloxone in opioid-dependent humans. Addiction 96, 230-242.
178. Strain EC, Stitzer ML, Liebson IA, et al. (1996) Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and Addiction Severity Index. Journal of Clinical Psychopharmacology 16, 58-67.
179. Strang J and Gossop M (1990) Comparisons of linear versus exponential methadone reduction curves in the detoxification of opiate addicts. Addictive Behaviors 15, 541-547.
180. Streeton C and Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment for alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol and Alcoholism 36, 544-552.
181. Stromberg MF, Mackler SA, and Volpicelli JR (2001) Effect of acampro-sate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 23, 109-116.
182. Substance Abuse and Mental Health Services Administration (SAMHSA) (2003) Overview of findings from the 2002 National Survey on Drug Use and Health (Office of Applied Studies, NHSDA Series H-21, DHHS Publication no. SMA 03-3774). Rockville, MD, USA.
183. Sullivan JT, Sykora K, Schneiderman J, et al. (1989) Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). British Journal of Addiction 84. 1353-1357.
184. Sullivan MA, Rothenberg JL, Vosburg SK, et al. (2006) Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage 1 trial. American Journal on Addictions 15, 150-159.
185. Tonstad S, Tonnesen P, Hajek P, et al. (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296, 64-71.
186. Torrens M, Fonseca F, Mateu G, et al. (2005) Efficacy of antidepressants in substance abuse disorders with and without comorbid depression. A systematic review and meta-analysis. Drug and Alcohol Dependence 78, 1-22.
187. Tucker T, Ritter A, Maher C, et al. (2004) Naltrexone maintenance for heroin dependence: uptake, attrition, and retention. Drug and Alcohol Review 23, 299-309.
188. UNODCCP (2002) Global Illicit Drug Trends 2002. United Nations Office for Drug Control and Crime Prevention, New York, USA.
189. Vining E, Kosten TR, and Kleber HD (1988) Clinical utility of rapid cloni-dine-naltrexone detoxification for opioid abuse. British Journal of Addiction 83, 567-575.
190. Vivitrol, http://vivitrol.com/pdf_docs/prescribing_info.pdf (accessed January 4, 2007).
191. Vocci FJ, Acri J, and Elkashef A (2005) Medication development for addictive disorders: the state of the science. British Journal of Addiction 162, 1432-1440.
192. Volpicelli JR, Alterman AL, and Hayashida M (1994) Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 51, 335-336.
193. Walsh SL, Preston KL, Stitzer ML, et al. (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology and Therapeutics 55, 569-580.
194. Weddington WW, Brown BS, Haertzen CA, et al. (1991) Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. American Journal of Drug and Alcohol Abuse 17, 137-152.
195. Weerts EM, Froestl W, Kaminski BJ, et al. (2007) Attenuation of cocaine-seeking by GABA(B) receptor agonists baclofen and CGP44532 but not the GABA reuptake inhibitor tiagabine in baboons. Drug and Alcohol Dependence 89(2/3), 206-13.
196. Wesson DR and Ling W (2003) The clinical opiate withdrawal scale (COWS). Journal of Psychoactive Drugs 35, 253-259.
197. Wetterling T, Kanitz RD, Veltrup C, et al. (1994) Clinical predictors of alcohol withdrawal delirium. Alcoholism, Clinical and Experimental Research 18, 1100-1102.
198. Wilens TE, Prince JB, Biederman J, et al. (1995) Attention deficit hyperactivity disorders in adult. Psychiatric Services 46, 761-763, 765.
199. Williams SH (2005) Medications for treating alcohol dependence. American Family Physician 72, 1775-1780.
200. Woody GE, O'Brien CP, and Rickels K (1975) Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. American Journal of Psychiatry 132.